Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea.
Yonsei Med J. 2011 Jan;52(1):196-8. doi: 10.3349/ymj.2011.52.1.196.
Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for multiple myeloma. The common adverse effects of bortezomib are asthenic conditions, gastrointestinal disturbances, and peripheral neuropathy. Here we describe a patient with dyspnea and general weakness because of complete atrioventricular block while receiving bortezomib. We immediately stopped bortezomib, and after inserting a permanent VDD pacemaker, the patients' symptoms disappeared.
硼替佐米是 26S 蛋白酶体抑制剂，是多发性骨髓瘤的有效治疗方法。硼替佐米的常见不良反应有乏力、胃肠道紊乱和周围神经病。我们在此描述 1 例接受硼替佐米治疗时因完全性房室传导阻滞而出现呼吸困难和全身无力的患者。我们立即停止使用硼替佐米，并在植入永久 VDD 起搏器后，患者症状消失。
